Philip Schein:  

Following completion of my medical training in Boston and Oxford I accepted the position of Senior Investigator in the Medicine Branch of the National Cancer Institute, and Head of Clinical Pharmacology.. I subseqently served as Scientific Director of the Lombardi Cancer Research Center, and the inaugural Scholl Professor of medical oncology and pharmacology. During that period of my career I was President of the American Society of Clinical Oncology, Chariman of the Medical Oncology Committee of the American Board of Internal Medicine, Chairman of the FDA's Oncologic Drugs Advisory Commttee and had a White House appointment to the National Cancer Advisory Board. In 1987 I founded a publicly-traded pharmaceutical company and took three projects through FDA and European regulatory approvals. After the company was sold I accepted an appointment at the University of Oxford as a Visiting Professor in Cancer Pharmacology for about a decade. I received an honorary doctorate of science (DSc (hon) from Rutgers University, The Rutgers Hall of Distinguished Alumni Award and a Doctor Honoris Causa from the National Universiy of Rosario, Argentina. I was also was elected a Fellow of the Royal College of Medicine, London, and and he Royal College of Medicine and Surgery, Glasgow. After having worked so intensively throughout my career in oncology and cancer research I am now having a difficult time slowing down. In response to the need to keep active I have constructed a menu of professional activities that serve to keep me sufficiently engaged. The last all consumiing assignment was my appointment to the ...Expand for more